Terapia Génica del Cáncer
TGC
Institute Catalá Oncología
Barcelona, EspañaPublicaciones en colaboración con investigadores/as de Institute Catalá Oncología (7)
2021
-
Lenvatinib in Patients With Advanced Grade 1/2 Pancreatic and Gastrointestinal Neuroendocrine Tumors: Results of the Phase II TALENT Trial (GETNE1509)
Journal of Clinical Oncology, Vol. 39, Núm. 20, pp. 2304-2312
2020
-
The PALBONET Trial: A Phase II Study of Palbociclib in Metastatic Grade 1 and 2 Pancreatic Neuroendocrine Tumors (GETNE-1407)
Oncologist, Vol. 25, Núm. 9, pp. 745-e1265
2019
-
Immunotherapy in organ-transplanted cancer patients: efficacy and risk of organ rejection
Annals of Oncology
-
Phase II Study of Everolimus and Octreotide LAR in Patients with Nonfunctioning Gastrointestinal Neuroendocrine Tumors: The GETNE1003_EVERLAR Study
Oncologist, Vol. 24, Núm. 1, pp. 38-46
2018
-
Early-drug development in the era of immuno-oncology: Are we ready to face the challenges?
Annals of Oncology, Vol. 29, Núm. 8, pp. 1727-1740
-
Outcomes after neoadjuvant treatment with gemcitabine and erlotinib followed by gemcitabine–erlotinib and radiotherapy for resectable pancreatic cancer (GEMCAD 10-03 trial)
Cancer Chemotherapy and Pharmacology, Vol. 82, Núm. 6, pp. 935-943
-
Psychological impact of multigene cancer panel testing in patients with a clinical suspicion of hereditary cancer across Spain
Psycho-Oncology, Vol. 27, Núm. 6, pp. 1530-1537